|
|
| (93 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{Hyperparathyroidism}}
| |
|
| |
|
| {{CMG}}; {{AE}} {{Anmol}} | | {{CMG}}; {{AE}} {{Anmol}} |
|
| |
|
| | ==Tables== |
| | {| class="wikitable" |
| | |+ |
| | !Diagnosis |
| | !Lab findings |
| | ! |
| | ! |
| | |- |
| | ! |
| | ! |
| | ! |
| | ! |
| | |- |
| | | |
| | | |
| | | |
| | | |
| | |- |
| | | |
| | | |
| | | |
| | | |
| | |- |
| | | |
| | | |
| | | |
| | | |
| | |} |
|
| |
|
| =Pathophysiology=
| |
| ==Pathophysiology==
| |
| *GSD type 1 results due to defects in either hydrolysis or transport of glucose-6-phosphate
| |
| *GSD type 1a is due to the deficiency of glucose-6-phosphatase enzyme (G6Pase).
| |
| *GDS type 1b is due to defect in glucose-6-phosphate transporter (T1 deficiency).
| |
| *G6Pase is primarily expressed in expressed primarily in the gluconeogenic the liver and kidney. It is also expressed to a lesser extent in the intestine and pancreas.
| |
| *Glucose-6-phosphatase catalyzes the conversion of glucose-6-phosphate to glucose during glycogenolysis and gluconeogenesis.
| |
| *This defects hinders the conversion of glucose-6 phosphate to glucose in organs.The inability of glucose-6-phosphate to leave cells leads to hypoglycemia.
| |
|
| |
| ==Genetics==
| |
| *80% Cases of GSD 1 are of GSD type 1a.
| |
| *G6Pase gene is located on chromosome locus 17q21.
| |
| *GSD type 1 follows autosomal recessive pattern.
| |
| ==References== | | ==References== |
| {{reflist|2}} | | {{reflist|2}} |
Latest revision as of 17:32, 14 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Tables
References